Effect of Pycnogenol® on attention-deficit hyperactivity disorder (ADHD): study protocol for a randomised controlled trial

被引:18
|
作者
Verlaet, Annelies A. J. [1 ]
Ceulemans, Berten [2 ]
Verhelst, Helene [3 ]
Van West, Dirk [4 ]
De Bruyne, Tess [1 ]
Pieters, Luc [1 ]
Savelkoul, Huub F. J. [5 ]
Hermans, Nina [1 ]
机构
[1] Univ Antwerp, Dept Pharmaceut Sci, Lab Nutr & Funct Food Sci, Univ Pl 1, B-2610 Antwerp, Belgium
[2] Univ Antwerp Hosp, Neurol, Wilrijkstr 10, B-2650 Edegem, Belgium
[3] Univ Hosp Ghent, Paediat Neurol, Pintelaan 185, B-9000 Ghent, Belgium
[4] Univ Child & Adolescent Psychiat, Hosp Networtk Antwerp, Lindendreef 1, B-2020 Antwerp, Belgium
[5] Wageningen Univ, Cell Biol & Immunol Grp, Elst 1, NL-6709 PG Wageningen, Netherlands
来源
TRIALS | 2017年 / 18卷
关键词
ADHD; ADD; Behaviour; Pycnogenol (R); Antioxidant; Polyphenols; Oxidative stress; Immunity; Catecholamines; PINE BARK EXTRACT; DEFICIT/HYPERACTIVITY DISORDER; OXIDATIVE STRESS; POLYPHENOLIC EXTRACT; CLINICAL-TRIALS; HUMAN HEALTH; CHILDREN; DISEASE; GLUTATHIONE; MICROBIOTA;
D O I
10.1186/s13063-017-1879-6
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Methylphenidate (MPH), the first choice medication for attention-deficit hyperactivity disorder (ADHD), is associated with serious adverse effects like arrhythmia. Evidence on the association of ADHD with immune and oxidant-antioxidant imbalances offers potential for antioxidant and/or immunomodulatory nutritional supplements as ADHD therapy. One small randomised trial in ADHD suggests, despite various limitations, therapeutic benefit from Pycnogenol (R), a herbal, polyphenol-rich extract. Methods: This phase III trial is a 10-week, randomised, double-blind, placebo and active treatment controlled multicentre trial with three parallel treatment arms to compare the effect of Pycnogenol r to MPH and placebo on the behaviour of 144 paediatric ADHD and attention-deficit disorder (ADD) patients. Evaluations of behaviour (measured by the ADHDRating Scale (primary endpoint) and the Social-emotional Questionnaire (SEQ)), immunity (plasma cytokine and antibody levels, white blood cell counts and faecal microbial composition), oxidative stress (erythrocyte glutathione, plasma lipid-soluble vitamins and malondialdehyde and urinary 8-OHdG levels, as well as antioxidant enzyme activity and gene expression), serum zinc and neuropeptide Y level, urinary catecholamines and physical complaints (Physical Complaints Questionnaire) will be performed in week 10 and compared to baseline. Acceptability evaluations will be based on adherence, dropouts and reports of adverse events. Dietary habits will be taken into account. Discussion: This trial takes into account comorbid behavioural and physical symptoms, as well as a broad range of innovative immune and oxidative biomarkers, expected to provide fundamental knowledge on ADHD aetiology and therapy. Research on microbiota in ADHD is novel. Moreover, the active control arm is rather unseen in research on nutritional supplements, but of great importance, as patients and parents are often concerned with the side effects of MPH.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Effect of Pycnogenol® on attention-deficit hyperactivity disorder (ADHD): study protocol for a randomised controlled trial
    Annelies A. J. Verlaet
    Berten Ceulemans
    Helene Verhelst
    Dirk Van West
    Tess De Bruyne
    Luc Pieters
    Huub F. J. Savelkoul
    Nina Hermans
    [J]. Trials, 18
  • [2] Acupuncture for attention deficit hyperactivity disorder (ADHD): study protocol for a randomised controlled trial
    Soon-Sang Hong
    Seung-Hun Cho
    [J]. Trials, 12
  • [3] Acupuncture for attention deficit hyperactivity disorder (ADHD): study protocol for a randomised controlled trial
    Hong, Soon-Sang
    Cho, Seung-Hun
    [J]. TRIALS, 2011, 12
  • [4] Digital cognitive training in children with attention-deficit/hyperactivity disorder: a study protocol of a randomised controlled trial
    Richmond, Sally
    Kirk, Hannah
    Gaunson, Tori
    Bennett, Meg
    Bellgrove, Mark A.
    Cornish, Kim
    [J]. BMJ OPEN, 2022, 12 (06):
  • [5] Neurofeedback as a nonpharmacological treatment for adults with attention-deficit/hyperactivity disorder (ADHD): study protocol for a randomized controlled trial
    Mayer, Kerstin
    Wyckoff, Sarah Nicole
    Fallgatter, Andreas J.
    Ehlis, Ann-Christine
    Strehl, Ute
    [J]. TRIALS, 2015, 16
  • [6] Neurofeedback as a nonpharmacological treatment for adults with attention-deficit/hyperactivity disorder (ADHD): study protocol for a randomized controlled trial
    Kerstin Mayer
    Sarah Nicole Wyckoff
    Andreas J Fallgatter
    Ann-Christine Ehlis
    Ute Strehl
    [J]. Trials, 16
  • [7] Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial
    Cooper, R. E.
    Williams, E.
    Seegobin, S.
    Tye, C.
    Kuntsi, J.
    Asherson, P.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S130 - S131
  • [8] Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial
    Cooper, Ruth E.
    Williams, Emma
    Seegobin, Seth
    Tye, Charlotte
    Kuntsi, Jonna
    Asherson, Philip
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 (08) : 795 - 808
  • [9] Attention-deficit/hyperactivity disorder (ADHD)
    Dalsgaard, Soren
    [J]. EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2013, 22 : S43 - S48
  • [10] Attention-deficit/hyperactivity disorder (ADHD)
    Søren Dalsgaard
    [J]. European Child & Adolescent Psychiatry, 2013, 22 : 43 - 48